I have a 51‑year‑old patient with headaches, dizziness and perceived high blood pressure who is taking amlodipine 10 mg daily, rosuvastatin 10 mg daily, hydrochlorothiazide 25 mg daily, and semaglutide (Wegovy); his in‑office blood pressure was 138/82 mmHg. As his primary care physician, what should I do?

Intensify Blood Pressure Therapy by Adding a Third Agent

Your patient's blood pressure of 138/82 mmHg represents inadequate control on dual therapy (amlodipine 10 mg + HCTZ 25 mg), and you should escalate to triple combination therapy by adding an ACE inhibitor or ARB, preferably as a single-pill combination. The headaches and dizziness may be related to suboptimal BP control, though you must also rule out other causes.

Immediate Assessment

First, confirm the BP elevation is sustained:

• Obtain out-of-office BP measurements (home BP monitoring or 24-hour ambulatory monitoring) to confirm the clinic reading 1, 2
• Assess medication adherence—up to 50% of patients discontinue medications on their own
• Evaluate the headaches and dizziness: Are they positional? Timing relative to medication dosing? Associated symptoms suggesting other etiologies (vision changes, neurologic deficits)?

Blood Pressure Management Strategy

Current Regimen Analysis

Your patient is on two first-line agents (amlodipine 10 mg + HCTZ 25 mg) but has not achieved target BP <130/80 mmHg. Both agents are at maximum or near-maximum doses:

• Amlodipine 10 mg is the maximum dose 3
• HCTZ 25 mg is standard dosing 1

Recommended Escalation

Add a renin-angiotensin system (RAS) blocker as the third agent 1, 2. The 2025 AHA/ACC guidelines explicitly recommend triple therapy with a RAS blocker (ACE inhibitor or ARB) + dihydropyridine calcium channel blocker + thiazide-type diuretic when dual therapy fails 1.

Strongly prefer a single-pill combination (SPC) containing all three agents to improve adherence 1, 2. Options include:

• Olmesartan/amlodipine/HCTZ 4
• Ramipril/amlodipine/HCTZ 5
• Other ACE inhibitor or ARB/amlodipine/HCTZ combinations

The evidence shows SPCs reduce therapeutic inertia, improve adherence, and achieve faster BP control compared to free combinations 5.

Dosing Considerations

• Start with standard doses of the RAS blocker component
• The 2024 ESC guidelines emphasize that most patients with confirmed hypertension (BP ≥140/90 mmHg) require combination therapy as initial treatment 2
• If triple therapy fails, consider adding spironolactone as a fourth agent 2

Addressing Symptoms

Headaches and Dizziness

These symptoms warrant careful evaluation:

Potential causes to consider:

1. Suboptimal BP control: Persistent hypertension can cause headaches
2. Medication-related: Amlodipine commonly causes dizziness (listed as common side effect) and headaches 3
3. Orthostatic hypotension: Check orthostatic vital signs, especially given the diuretic use
4. Other etiologies: Rule out secondary causes if symptoms persist after BP optimization

Management approach:

• Recheck BP after adding the third agent (assess as early as 4 weeks) 1
• If symptoms persist despite BP control, consider whether amlodipine side effects are contributing
• Monitor for orthostatic symptoms, particularly in this 51-year-old patient on diuretic therapy

Lipid Management

The rosuvastatin 10 mg is appropriate for cardiovascular risk reduction 6. The combination of rosuvastatin with amlodipine is safe and well-tolerated 7, 8. No adjustment needed unless LDL-C is not at goal.

Wegovy Considerations

Continue semaglutide (Wegovy) for weight management, which will provide additional cardiovascular benefit and may help with BP control through weight reduction.

Common Pitfalls to Avoid

1. Therapeutic inertia: Don't delay intensification when BP remains elevated on dual therapy
2. Ignoring out-of-office BP: Clinic readings alone may not reflect true BP control
3. Polypharmacy without SPCs: Using multiple separate pills reduces adherence significantly
4. Dismissing symptoms: Headaches and dizziness require evaluation even while optimizing BP
5. Underdosing: Ensure you're using adequate doses before adding agents, though in this case both current agents are appropriately dosed

Follow-Up Plan

• Reassess BP in 4 weeks after adding the RAS blocker 1
• Monitor potassium and creatinine after starting ACE inhibitor/ARB
• Evaluate symptom resolution with improved BP control
• Consider 24-hour ambulatory BP monitoring if symptoms persist or BP control remains uncertain
• Target BP <130/80 mmHg per current guidelines 1, 2